Work

Lenvatinib, gemcitabine, and oxaliplatin for 67 patients with fibrolamellar carcinoma.

Year: 2024

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2024.42.16_suppl.e16151

Authors: Paul Kent, Tom Stockwell, Jordan C Tasse, Abhinav Humar, Tom Kato, Oliver M Fisher, Darrell Yamashiro, Reid Michael Davison, Albert Cornelius, Susanne M. Swasey, Matthew Dixon, Christopher W. Seder, Erik Schadde

Institutions: Rush University Medical Center, UPMC Health System, University of Pittsburgh Medical Center, St George Hospital, Columbia University Irving Medical Center, The University of Texas Health Science Center at Houston, Helen DeVos Children's Hospital, Rush University, University of Zurich

Language: English

Topic: Hepatocellular Carcinoma Treatment and Prognosis

Subfield: Hepatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4400415735

Cites:

Cited by: 2

Related to: 10